Law360, New York (October 20, 2011, 7:57 PM ET) -- Impax Laboratories Inc. on Thursday settled a patent infringement suit brought by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in New Jersey over the generic-drug maker’s efforts to market a version of cholesterol drug Trilipix.
Under the settlement, Impax can launch its generic version of Abbot’s Trilipix on Jan. 1, 2014, or as early as July 15, 2013, under certain conditions, though those were not disclosed in a filing with the U.S. Securities and Exchange Commission by the generics maker.
Impax, the first company to file...
Abbott, Fournier Settle With Impax Over Generic Trilipix
To view the full article, take a free trial now.
